The same analysis in CRC and melanoma patient-derived xenograft (PDX) samples (Fig. 1i–l) demonstrated markedly low BCL-XL expression in melanoma PDXs vs. CRC (Fig. 1i, k), whereas MCL1 expression was broadly similar (Fig. 1i, j). The gene discussed is BCL2L1; the disease is melanoma.